Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone marrow transplantation for multiple sclerosis

R K Burt, W Burns, A Hess

    Bone Marrow Transplantation
    |July 1, 1995
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Novel insights into diminished cardiac reserve in non-obstructive hypertrophic cardiomyopathy from four-dimensional flow cardiac magnetic resonance component analysis.

    European heart journal. Cardiovascular Imaging·2023
    Same author

    Preparation of Polyfunctionalized Aromatic Nitriles from Aryl Oxazolines.

    Chemistry (Weinheim an der Bergstrasse, Germany)·2021
    Same author

    Phase I clinical trial of an antithrombotic drug protocol combining apixaban and clopidogrel in dogs.

    Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology·2021
    Same author

    Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain - Study protocol for a randomized double-blind controlled study.

    Contemporary clinical trials communications·2021
    Same author

    Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2021
    Same author

    Molecular imaging in nuclear cardiology: Pathways to individual precision medicine.

    Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2020
    Same journal

    ALLOPLUS: allogeneic hematopoietic stem cell transplantation in children and adult people living with human immunodeficiency virus, a retrospective study of the SFGM-TC.

    Bone marrow transplantation·2026
    Same journal

    Epigenetic priming with azacitidine-BEAM versus decitabine-BEAM conditioning for autologous transplantation in non-Hodgkin's lymphoma.

    Bone marrow transplantation·2026
    Same journal

    CHIME: a novel HLA eplet model associates with non-relapse mortality in haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide.

    Bone marrow transplantation·2026
    Same journal

    Transplant outcomes for patients with severe acquired aplastic anemia over the age of 40 using busulfan, fludarabine, reduced-dose cyclophosphamide, and anti-thymocyte globulin conditioning regimen.

    Bone marrow transplantation·2026
    Same journal

    A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

    Bone marrow transplantation·2026
    Same journal

    Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

    Bone marrow transplantation·2026
    See all related articles

    Hematopoietic stem cell transplantation (HSCT), or bone marrow transplantation (BMT), may offer benefits for multiple sclerosis (MS) patients. Careful patient selection and investigational protocols are crucial due to potential risks.

    Area of Science:

    • Neurology
    • Immunology
    • Hematology

    Background:

    • Multiple sclerosis (MS) is a leading cause of neurologic disability.
    • Animal studies indicate potential benefits of bone marrow transplantation (BMT) for MS.
    • The risk-benefit ratio of BMT for MS requires careful consideration.

    Discussion:

    • For patients with progressive MS, survival rates are comparable to certain lymphomas.
    • Malignant MS cases show survival rates similar to chronic phase chronic myeloid leukemia (CML).
    • Progressive pain and disability in advanced MS can render life intolerable.

    Key Insights:

    • BMT may be a viable therapeutic option for carefully selected MS patients.
    • Investigational protocols are essential to manage the risks associated with BMT.

    Related Experiment Videos

  • The potential to alleviate severe MS symptoms may justify the risks of BMT.

    • Outlook:

    • Further research is needed to optimize BMT protocols for MS.
    • Identifying ideal patient candidates for BMT in MS is critical.
    • Evaluating long-term outcomes and safety profiles of BMT in MS is paramount.